Poseida Therapeutics, Inc.
PSTXDelisted Jan 8, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001661460
Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding Poseida Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 93 | 1 | 96 | +4 |
| Shares | 53.1M | 4.91M | 53.6M | +5.46M (+11.3%) |
| Value | $154.9M | $14.3M | $153.4M | +$12.8M (+9.1%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Poseida Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 5,123,969 | $14.7M | 0.00% |
| Woodline Partners LP | 478,861 | $1.37M | 0.01% |
| Arrowstreet Capital, Limited Partnership | 351,366 | $1.00M | 0.00% |
| Fred Alger Management, LLC | 128,970 | $368.9K | 0.00% |
| Advantage Alpha Capital Partners LP | 99,566 | $284.8K | 0.06% |
| Privium Fund Management B.V. | 77,500 | $221.7K | 0.06% |
| Two Sigma Advisers, LP | 37,400 | $107.0K | 0.00% |
| SG Americas Securities, LLC | 24,417 | $70.0K | 0.00% |
| State of Wyoming | 18,749 | $53.6K | 0.01% |
| Intech Investment Management LLC | 16,159 | $46.2K | 0.00% |
| ProShare Advisors LLC | 12,972 | $37.1K | 0.00% |
| Virtu Financial LLC | 13,035 | $37.0K | 0.00% |
| Sherbrooke Park Advisers LLC | 10,696 | $30.6K | 0.01% |
| Bessemer Group Inc | 425 | $1.00K | 0.00% |
| Smartleaf Asset Management LLC | 233 | $675 | 0.00% |
| Sterling Capital Management LLC | 176 | $503 | 0.00% |
| Allspring Global Investments Holdings, LLC | 34 | $97 | 0.00% |
Sold out (13)
Institutions that held Poseida Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Octagon Capital Advisors LP | 736,000 | $2.15M |
| Atom Investors LP | 395,768 | $1.16M |
| Cantor Fitzgerald, L. P. | 50,205 | $146.6K |
| Dynamic Technology Lab Private Ltd | 27,031 | $79.0K |
| Susquehanna International Group, LLP | 16,006 | $46.7K |
| Principal Financial Group Inc | 12,006 | $35.1K |
| Graham Capital Management, L.P. | 11,004 | $32.1K |
| Verition Fund Management LLC | 10,673 | $31.2K |
| Group One Trading, L.P. | 9,216 | $26.9K |
| Central Bank & Trust Co | 7,608 | $22.2K |
| US Bancorp | 5,200 | $15.2K |
| Simplex Trading, LLC | 1,335 | $3.00K |
| nVerses Capital, LLC | 800 | $2.34K |
Not filed for Q3 2024 yet (1)
Institutions that held Poseida Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 4,905,160 | $14.3M |